Cited by 2,561Schizophrenia research and treatmentMental Health and PsychiatryTreatment of Major Depression

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

Leucht, Stefan, Cipriani, Andrea, Spineli, Loukia, Mavridis, Dimitris, Örey, Deniz, Richter, Franziska, Samara, Myrto, Barbui, Corrado, Engel, Rolf R, Geddes, John R, Kissling, Werner, Stapf, Marko Paul, Lässig, Bettina, Salanti, Georgia, Davis, John M·2013·The Lancet

DOI 10.1016/s0140-6736(13)60733-3

Open this paper in CoChat — free account

Abstract

Background The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative efficacy, risk of all-cause discontinuation, and major side-effects of antipsychotic drugs.Methods We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's specialised register, Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for reports published up to Sept 1, 2012. Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. We excluded trials done in patients with predominant negative symptoms, concomitant medical illness, or treatment resistance, and those done in stable patients. Data for seven outcomes were independently extracted by two reviewers. The primary outcome was efficacy, as measured by mean overall change in symptoms. We also examined all-cause discontinuation, weight gain, extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation.Findings We identified 212 suitable trials, with data for 43 049 participants. All drugs were significantly more effective than placebo. The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73-1·03; amisulpride 0·66, 0·53-0·78; olanzapine 0·59, 0·53-0·65; risperidone 0·56, 0·50-0·63; paliperidone 0·50, 0·39-0·60; zotepine 0·49, 0·31-0·66; haloperidol 0·45, 0·39-0·51; quetiapine 0·44, 0·35-0·52; aripiprazole 0·43, 0·34-0·52; sertindole 0·39, 0·26-0·52; ziprasidone 0·39, 0·30-0·49; chlorpromazine 0·38, 0·23-0·54; asenapine 0·38, 0·25-0·51; lurasidone 0·33, 0·21-0·45; and iloperidone 0·33, 0·22-0·43. Odds ratios compared with placebo for all-cause discontinuation ranged from 0·43 for the best drug (amisulpride) to 0·80 for the worst drug (haloperidol); for extrapyramidal side-effects 0·30 (clozapine) to 4·76 (haloperidol); and for sedation 1·42 (amisulpride) to 8·82 (clozapine). Standardised mean differences compared with placebo for weight gain varied from -0·09 for the best drug (haloperidol) to -0·74 for the worst drug (olanzapine), for prolactin increase 0·22 (aripiprazole) to -1·30 (paliperidone), and for QTc prolongation 0·10 (lurasidone) to -0·90 (sertindole). Efficacy outcomes did not change substantially after removal of placebo or haloperidol groups, or when dose, percentage of withdrawals, extent of blinding, pharmaceutical industry sponsorship, study duration, chronicity, and year of publication were accounted for in meta-regressions and sensitivity analyses.Interpretation Antipsychotics differed substantially in side-effects, and small but robust differences were seen in efficacy. Our findings challenge the straightforward classification of antipsychotics into first-generation and second-generation groupings. Rather, hierarchies in the different domains should help clinicians to adapt the choice of antipsychotic drug to the needs of individual patients. These findings should be considered by mental health policy makers and in the revision of clinical practice guidelines.Funding None.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(13)60733-3

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,603
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J., Green, S. R., & Higgins, J. (2008) · Cited by 5,544
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Self-citation
Checking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521

Show all 61 references

Research works printed but not linked: 1

Leucht, 2009, A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia, Am J Psychiatry, 166, 152, 10.1176/appi.ajp.2008.08030368 · DOI

Sorted by citations

Items 301–400 of 1,006

Stopping and switching antipsychotic drugs
Keks, N., Schwartz, D., & Hope, J. (2019) · Australian Prescriber · doi:10.18773/austprescr.2019.052 · Cited by 63
Pharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysis
Gressier, F., Porcelli, S., Calati, R., & Serretti, A. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.12.035 · Cited by 64
Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study
Durgam, S., Greenberg, W. M., Li, D., Lu, K., Laszlovszky, I., Németh, G., Migliore, R., & Volk, S. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4450-3 · Cited by 64
New discoveries for an old drug: a review of recent olanzapine research
Meftah, A. M., Deckler, E., Citrome, L., & Kantrowitz, J. T. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1701823 · Cited by 69
Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
Gomes, F. V., & Grace, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094467 · Cited by 66
An Overview of the Association between Schizotypy and Dopamine
Mohr, C., & Ettinger, U. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00184 · Cited by 63
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel
Citrome, L. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12714 · Cited by 63
Clozapine for Treatment-Resistant Schizophrenia: Still the Gold Standard?
Taylor, D. M. (2017) · CNS Drugs · doi:10.1007/s40263-017-0411-6 · Cited by 63
Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6‐week, randomized, double‐blind, placebo‐controlled study
Ishigooka, J., Iwashita, S., & Tadori, Y. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12682 · Cited by 63
Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS®) in the Swedish COAST-study
Brain, C., Allerby, K., Sameby, B., Quinlan, P. S., Joas, E., Karilampi, U., Lindström, E., Eberhard, J., Burns, T., & Wærn, M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.09.001 · Cited by 62
Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges
Lee, J., Nam, D., & Lee, J. (2016) · Oncology Letters · doi:10.3892/ol.2016.4074 · Cited by 63
Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile
Jaeschke, R. R., Sowa-Kućma, M., Pańczyszyn-Trzewik, P., Misztak, P., Styczeń, K., & Datka, W. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.04.002 · Cited by 65
Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia
Marteene, W., Winckel, K., Hollingworth, S., Kisely, S. R., Gallagher, E., Hahn, M., Ebdrup, B. H., Firth, J., & Siskind, D. J. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1674809 · Cited by 62
Clinical trials registries are under-utilized in the conduct of systematic reviews: a cross-sectional analysis
Jones, C. W., Keil, L. G., Weaver, M. A., & Platts-Mills, T. F. (2014) · Systematic Reviews · doi:10.1186/2046-4053-3-126 · Cited by 61
Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review
Plasencia-García, B. O., Rodríguez-Menéndez, G., Rico-Rangel, M. I., Rubio-García, A., Torelló-Iserte, J., & Crespo‐Facorro, B. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05716-4 · Cited by 61
Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: State-of-the-art and future perspectives
Chang, S.-C., Goh, K. K., & Lu, M. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i10.696 · Cited by 72
Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms
McCutcheon, R. A., Beck, K., Bloomfield, M., Marques, T. R., Rogdaki, M., & Howes, O. D. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115576688 · Cited by 61
Stem cell-derived interneuron transplants as a treatment for schizophrenia: preclinical validation in a rodent model
Donegan, J. J., Tyson, J. A., Branch, S. Y., Beckstead, M. J., Anderson, S. A., & Lodge, D. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.121 · Cited by 60
Automated psychological therapy using virtual reality (VR) for patients with persecutory delusions: study protocol for a single-blind parallel-group randomised controlled trial (THRIVE)
Freeman, D. H., Lister, R., Waite, F., Yu, L., Slater, M., Dunn, G., & Clark, D. M. (2019) · Trials · doi:10.1186/s13063-019-3198-6 · Cited by 66
Modulation of extrasynaptic GABAA alpha 5 receptors in the ventral hippocampus normalizes physiological and behavioral deficits in a circuit specific manner
Donegan, J. J., Boley, A. M., Yamaguchi, J., Toney, G. M., & Lodge, D. J. (2019) · Nature Communications · doi:10.1038/s41467-019-10800-1 · Cited by 59
The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: A double-blind, randomized, placebo-controlled trial
Tek, C., Palmese, L. B., Krystal, A. D., Srihari, V. H., DeGeorge, P. C., Reutenauer, E. L., & Guloksuz, S. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.10.002 · Cited by 59
“sedating antipsychotics have all been associated with weight gain and metabolic syndrome (Leucht et al., 2013); and 3.”
Background
Dynamic ElecTronic hEalth reCord deTection (DETECT) of individuals at risk of a first episode of psychosis: a case-control development and validation study
Raket, L. L., Jaskolowski, J., Kinon, B. J., Brasen, J. C., Jönsson, L., Wehnert, A., & Fusar-Poli, P. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30024-8 · Cited by 60
Unmet needs in the management of schizophrenia
Torres‐González, F., Ibáñez-Casas, I., Saldivia, S., Ballester, D., Pamela Grandón, F., Moreno‐Küstner, B., Xavier, M., & Gómez-Beneyto, M. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s41063 · Cited by 71
The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for its Methodology and a Review of the Effectiveness of Switching Antipsychotics
Leucht, S., Rossum, I. W.-V., Heres, S., Arango, C., Fleischhacker, W. W., Glenthoj, B. Y., Leboyer, M., Leweke, F. M., Lewis, S. W., McGuire, P. K., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv019 · Cited by 60
Self-citation
Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists
Pisano, S., Catone, G., Veltri, S., Lanzara, V., Pozzi, M., Clementi, E., Iuliano, R., Riccio, M. P., Radice, S., Molteni, M., et al. (2016) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-016-0259-2 · Cited by 60
Leptin/Adiponectin ratio as a potential biomarker for metabolic syndrome in patients with schizophrenia
Chen, V. C., Chen, C.-H., Chiu, Y.-H., Lin, T., Li, F.-C., & Lu, M. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.03.021 · Cited by 60
Concentration–Effect Relationships of Psychoactive Drugs and the Problem to Calculate Therapeutic Reference Ranges
Hiemke, C. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000582 · Cited by 60
Practical Use of Pharmacotherapy for Obesity
Igel, L. I., Kumar, R. B., Saunders, K. H., & Aronne, L. J. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.049 · Cited by 59
Recent advances in understanding schizophrenia
Haller, C. S., Padmanabhan, J. L., Lizano, P. L., Torous, J. B., & Keshavan, M. S. (2014) · F1000Prime Reports · doi:10.12703/p6-57 · Cited by 65
Cardiovascular safety of antipsychotics: a clinical overview
Polcwiartek, C., Kragholm, K. H., Schjerning, O., Graff, C., & Nielsen, J. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1161021 · Cited by 60
Genetics of Schizophrenia: Ready to Translate?
Foley, C., Corvin, A. P., & Nakagome, S. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0807-5 · Cited by 61
A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia
Macek, T. A., McCue, M., Dong, X., Hanson, E., Goldsmith, P., Affinito, J., & Mahableshwarkar, A. R. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.08.028 · Cited by 59
A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis
Giovannoni, G., Lang, S., Wolff, R. F., Duffy, S., Hyde, R., Kinter, E. T., Wakeford, C., Sormani, M. P., & Kleijnen, J. (2020) · Neurology and Therapy · doi:10.1007/s40120-020-00212-5 · Cited by 58
Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process
Kadra-Scalzo, G., Stewart, R. J., Shetty, H., Jackson, R., Greenwood, M., Roberts, A., Chang, C., MacCabe, J. H., & Hayes, R. D. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0557-z · Cited by 58
A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
Tandon, R., Cucchiaro, J. B., Phillips, D., Hernandez, D., Mao, Y., Pikalov, A., & Loebel, A. D. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115620460 · Cited by 58
Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies
Correll, C. U., Skuban, A., Hobart, M., Ouyang, J., Weiller, E., Weiss, C., & Kane, J. M. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.04.012 · Cited by 58
Embracing Psychosis: A Cognitive Insight Intervention Improves Personal Narratives and Meaning-Making in Patients With Schizophrenia
Moritz, S., Mahlke, C., Westermann, S., Ruppelt, F., Lysaker, P. H., Bock, T. A., & Andreou, C. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx072 · Cited by 60
What matters to patients? A systematic review of preferences for medication-associated outcomes in mental disorders
Eiring, Ø., Landmark, B. F., Aas, E., Salkeld, G., Nylenna, M., & Nytrøen, K. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007848 · Cited by 57
Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia
Achtyes, E. D., Simmons, A., Skabeev, A., Levy, N., Jiang, Y., Marcy, P., & Weiden, P. J. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1856-y · Cited by 57
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia
Potkin, S. G., Kunovac, J. L., Silverman, B. L., Simmons, A., Jiang, Y., DiPetrillo, L., & McDonnell, D. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12769 · Cited by 57
Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics
Hargarter, L., Chérubin, P., Bergmans, P., Keim, S., Rancāns, E., Bez, Y., Parellada, E., Carpiniello, B., Vidailhet, P., & Schreiner, A. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.11.006 · Cited by 57
Intramuscular olanzapine for agitated patients: A systematic review and meta-analysis of randomized controlled trials
Kishi, T., Matsunaga, S., & Iwata, N. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.07.005 · Cited by 57
Second-generation antipsychotics and adiponectin levels in schizophrenia: A comparative meta-analysis
Bartoli, F., Crocamo, C., Clerici, M., & Carrà, G. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.06.011 · Cited by 58
Baseline brain structural and functional predictors of clinical outcome in the early course of schizophrenia
Doucet, G. E., Moser, D. A., Luber, M. J., Leibu, E., & Frangou, S. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0269-0 · Cited by 57
Brexpiprazole: A Review in Schizophrenia
Frampton, J. E. (2019) · Drugs · doi:10.1007/s40265-019-1052-5 · Cited by 57
Psychosocial interventions for people with schizophrenia or psychosis on minimal or no antipsychotic medication: A systematic review
Cooper, R. E., Laxhman, N., Crellin, N. E., Moncrieff, J., & Priebe, S. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.05.020 · Cited by 62
Antipsychotic drugs and sudden cardiac death: A literature review of the challenges in the prediction, management, and future steps
Zhu, J., Hou, W., Xu, Y., Ji, F., Wang, G., Chen, C., Lin, C., Lin, X., Li, J., Zhuo, C., et al. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112598 · Cited by 56
Developments in Biological Mechanisms and Treatments for Negative Symptoms and Cognitive Dysfunction of Schizophrenia
Wu, Q., Wang, X., Wang, Y., Long, Y., Zhao, J., & Wu, R. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00740-6 · Cited by 59
Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among U.S. Veterans Health Administration patients with dual diagnoses
Rubinsky, A. D., Chen, C., Batki, S. L., Williams, E. C., & Harris, A. H. S. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.07.016 · Cited by 56
Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study
Nosè, M., Bighelli, I., Castellazzi, M., Martinotti, G., Carrà, G., Lucii, C., Ostuzzi, G., Sozzi, F., Barbui, C., & the STAR NETWORK GROUP (2015) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796015000906 · Cited by 56
Self-citation
Genetics of Common Antipsychotic-Induced Adverse Effects
MacNeil, R. R., & Müller, D. J. (2016) · Complex Psychiatry · doi:10.1159/000445802 · Cited by 57
Intranasal Zotepine Nanosuspension: intended for improved brain distribution in rats
Pailla, S. R., Talluri, S., Rangaraj, N., Ramavath, R., Challa, V. S., Doijad, N. S., & Sampathi, S. (2019) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-019-00281-4 · Cited by 56
Consenso español sobre los riesgos y detección de la hiperprolactinemia iatrogénica por antipsicóticos
Montejo, Á. L., Arango, C., Bernardo, M., Carrasco, J. L., Crespo-Facorro, B., Cruz, J. J., del Pino, J., García Escudero, M. A., García Rizo, C., González-Pinto, A., et al. (2016) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2015.11.003 · Cited by 55
The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
Citrome, L., Stensbøl, T. B., & Maeda, K. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1086269 · Cited by 63
Speaking-Induced Suppression of the Auditory Cortex in Humans and Its Relevance to Schizophrenia
Whitford, T. J. (2019) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2019.05.011 · Cited by 64
Oral Anticoagulant Agents in Patients With Atrial Fibrillation and CKD: A Systematic Review and Pairwise Network Meta-analysis
Su, X., Yan, B., Wang, L., Lv, J., Cheng, H., & Chen, Y. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.02.328 · Cited by 54
Evidence-based public policy making for medicines across countries: findings and implications for the future
Godman, B., Fadare, J. O., Kwon, H.-Y., Dias, C. Z., Kurdi, A. B., Godói, I. P. D., Kibuule, D., Hoxha, I., Opanga, S. A., Saleem, Z., et al. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0273 · Cited by 59
Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe
Raschi, E., Poluzzi, E., Godman, B., Koci, A., Moretti, U., Kalaba, M., Bennie, M., Barbui, C., Wettermark, B., Sturkenboom, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081208 · Cited by 54
Self-citation
Yoga versus standard care for schizophrenia
Broderick, J. M., Knowles, A., Chadwick, J., & Vancampfort, D. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010554.pub2 · Cited by 55
Cardiovascular Disease in Clozapine-Treated Patients: Evidence, Mechanisms and Management
Ronaldson, K. J. (2017) · CNS Drugs · doi:10.1007/s40263-017-0461-9 · Cited by 55
Decomposition of the Total Effect in the Presence of Multiple Mediators and Interactions.
Bellavia, A., & Valeri, L. (2018) · American Journal of Epidemiology · doi:10.1093/aje/kwx355 · Cited by 59
Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies
Molden, E. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1974400 · Cited by 54
Dose-Specific Adverse Drug Reaction Identification in Electronic Patient Records: Temporal Data Mining in an Inpatient Psychiatric Population
Eriksson, R., Werge, T. M., Jensen, L. J., & Brunak, S. (2014) · Drug Safety · doi:10.1007/s40264-014-0145-z · Cited by 56
Toward the Identification of Peripheral Epigenetic Biomarkers of Schizophrenia
Guidotti, A., Auta, J., Davis, J. M., Dong, E., Gavin, D. P., Grayson, D. R., Sharma, R. P., Smith, R. C., Tueting, P. A., & Zhubi, A. (2014) · Journal of Neurogenetics · doi:10.3109/01677063.2014.892485 · Cited by 54
Self-citation
Second-Generation Antipsychotics’ Effectiveness and Tolerability: A Review of Real-World Studies in Patients with Schizophrenia and Related Disorders
Fabrazzo, M., Cipolla, S., Camerlengo, A., Perris, F., & Catapano, F. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154530 · Cited by 54
Pathophysiology, prognosis and treatment of tardive dyskinesia
Takeuchi, H., Mori, Y., & Tsutsumi, Y. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221117313 · Cited by 58
Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia
Achtyes, E. D., Hopkins, S. C., Dedic, N., Dworak, H., Zeni, C. M., & Koblan, K. S. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01580-3 · Cited by 61
Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine
Muscatello, M. R. A., Bruno, A., Fazio, P. D., Segura‐Garcìa, C., Pandolfo, G., & Zoccali, R. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.956082 · Cited by 58
Attrition in trials evaluating complex interventions for schizophrenia: Systematic review and meta-analysis
Szymczyńska, P., Walsh, S., Greenberg, L., & Priebe, S. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.02.009 · Cited by 62
Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method
Rothe, P., Heres, S., & Leucht, S. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.07.033 · Cited by 54
Self-citation
Measurement and Management of QT Interval Prolongation for General Physicians
Indraratna, P., Tardo, D. T., Delves, M., Szirt, R., & Ng, B. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05477-7 · Cited by 53
Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders
Harrow, M., Jobe, T. H., & Tong, L. (2021) · Psychological Medicine · doi:10.1017/s0033291720004778 · Cited by 53
Global Scientific Outputs of Schizophrenia Publications From 1975 to 2020: a Bibliometric Analysis
Kıraz, S., & Demir, E. (2021) · Psychiatric Quarterly · doi:10.1007/s11126-021-09937-4 · Cited by 58
Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance
Haddad, P., Kishimoto, T., Correll, C., & Kane, J. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000160 · Cited by 58
Antipsychotics Promote Metabolic Disorders Disrupting Cellular Lipid Metabolism and Trafficking
Vantaggiato, C., Panzeri, E., Citterio, A., Orso, G., & Pozzi, M. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.01.003 · Cited by 56
Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: Findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey
Dong, M., Zeng, L., Zhang, Q., Yang, S.-Y., Chen, L., Najoan, E., Kallivayalil, R. A., Viboonma, K., Jamaluddin, R., Javed, A., et al. (2019) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2019.08.010 · Cited by 59
Risk of Breast Cancer With Prolactin Elevating Antipsychotic Drugs
Rahman, T., Sahrmann, J. M., Olsen, M. A. A., Nickel, K. B., Miller, J. P., Ma, C. X., & Grucza, R. A. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001513 · Cited by 53
Biological treatment of Acute Agitation Or Aggression with Schizophrenia Or Bipolar Disorder in the Inpatient Setting
Correll, C. U., Yu, X., Xiang, Y., Kane, J. M., & Masand, P. S. (2017) · Annals of Clinical Psychiatry · doi:10.1177/104012371702900203 · Cited by 52
Psychotic, Mood, and Anxiety Disorders and Venous Thromboembolism: A Systematic Review and Meta-Analysis
Kowal, C., Peyre, H., Amad, A., Pélissolo, A., Leboyer, M., Schürhoff, F., & Pignon, B. (2020) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000863 · Cited by 53
Quetiapine for primary insomnia: Consider the risks
Modesto‐Lowe, V., Harabasz, A. K., & Walker, S. A. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20031 · Cited by 52
Anesthetic Considerations for Patients on Psychotropic Drug Therapies
Harbell, M. W., Dumitrascu, C., Bettini, L. M., Yu, S., Thiele, C. M., & Koyyalamudi, V. (2021) · Neurology International · doi:10.3390/neurolint13040062 · Cited by 60
Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review
Bo, Q., Wang, Z., Li, X., Ma, X., Wang, C., & de León, J. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.01.031 · Cited by 52
Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials
Zheng, W., Li, X.-H., Yang, X.-H., Cai, D.-B., Ungvari, G. S., Ng, C. H., Sb, W., Wang, Y.-Y., Ning, Y.-P., & Xiang, Y. (2017) · Psychological Medicine · doi:10.1017/s0033291717001271 · Cited by 52
A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers
Silverman, B. L., Martin, W. F., Memişoğlu, A., DiPetrillo, L., Correll, C. U., & Kane, J. M. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.10.014 · Cited by 52
A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia
Forbes, A., Hobart, M., Ouyang, J., Shi, L., Pfister, S., & Hakala, M. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy002 · Cited by 52
In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
Luykx, J. J., Stam, N., Tanskanen, A. J., Tiihonen, J., & Taipale, H. T. (2020) · The British Journal of Psychiatry · doi:10.1192/bjp.2019.267 · Cited by 54
Up-to-date expert opinion on the safety of recently developed antipsychotics
Orsolini, L., Berardis, D. D., & Volpe, U. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1795126 · Cited by 52
Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders
Kuusimäki, T., Al‐Abdulrasul, H., Kurki, S. H., Hietala, J. A., Hartikainen, S. A., Koponen, M., Tolppanen, A., & Kaasinen, V. (2021) · Movement Disorders · doi:10.1002/mds.28484 · Cited by 55
Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
Nielsen, J., Jensen, S. O. W., Friis, R., Valentin, J., & Correll, C. (2015) · Schizophrenia bulletin · doi:10.1093/schbul/sbu128 · Cited by 56
Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
Druais, S., Doutriaux, A., Cognet, M., Godet, A., Lançon, C., Lévy, P., Samalin, L., & Guillon, P. (2016) · PharmacoEconomics · doi:10.1007/s40273-015-0348-x · Cited by 55
Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms
Li, M. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116654697 · Cited by 51
Direct comparison of tricyclic and serotonin-reuptake inhibitor antidepressants in randomized head-to-head trials in acute major depression: Systematic review and meta-analysis
Undurraga, J. P., & Baldessarini, R. J. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117711709 · Cited by 51
Clozapine in Reducing Aggression and Violence in Forensic Populations
Patchan, K. M., Vyas, G. R., Hackman, A. L., Mackowick, M., Richardson, C. M., Love, R. C., Wonodi, I., Sayer, M. A., Glassman, M., Feldman, S. M., et al. (2017) · Psychiatric Quarterly · doi:10.1007/s11126-017-9521-z · Cited by 51
Targeting Recovery in Persistent Persecutory Delusions: A Proof of Principle Study of a New Translational Psychological Treatment (the Feeling Safe Programme)
Freeman, D., Bradley, J., Waite, F., Sheaves, B., DeWeever, N., Bourke, E., McInerney, J., Evans, N., Černis, E., Lister, R., et al. (2016) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s1352465816000060 · Cited by 50
“The first line treatment, antipsychotic medication, has effect sizes (standardized mean differences) varying between 0.33 and 0.88 (median=0.44) (Leucht et al., 2013), with problems of major side-effects, poor compliance, and residual problems.”
BackgroundInfluential
Flexible scaffold-based cheminformatics approach for polypharmacological drug design
Chen, Z., Yu, J., Wang, H., Xu, P., Fan, L., Sun, F., Huang, S., Zhang, P., Huang, H., Gu, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.034 · Cited by 53
5 A s T eam obesity intervention in primary care: development and evaluation of shared decision‐making weight management tools
Osunlana, A. M., Asselin, J. D., Anderson, R., Ogunleye, A. A., Cave, A., Sharma, A. M., & Campbell-Scherer, D. L. (2015) · Clinical Obesity · doi:10.1111/cob.12105 · Cited by 50
A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults
Citrome, L., Kalsekar, I. D., Baker, R. A., & Hebden, T. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.908280 · Cited by 50
Olanzapine and clozapine differently affect sleep in patients with schizophrenia: Results from a double-blind, polysomnographic study and review of the literature
Kluge, M., Schacht, A., Himmerich, H., Rummel‐Kluge, C., Wehmeier, P. M., Dalal, M. A., Hinze‐Selch, D., Kraus, T., Dittmann, R., Pollmächer, T., et al. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.11.009 · Cited by 50
Negative symptoms in schizophrenia
Mahintamani, T., Mitra, S., Kavoor, A. R., & Nizamie, S. (2016) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_30_15 · Cited by 50
Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring
Sultan, R. S., Olfson, M., Correll, C. U., & Duncan, E. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m11152 · Cited by 50

Authors: Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., Kissling, W., Stapf, M. P., Lässig, B., Salanti, G., & Davis, J. M.
Affiliations: TUM Klinikum (DE)
University of Verona (IT)
University of Ioannina (GR)
Ludwig-Maximilians-Universität München (DE)
Warneford Hospital (GB)
University of Illinois Chicago (US)
Corresponding author: Leucht, Stefan
ORCID: Leucht, Stefan
Cipriani, Andrea
Spineli, Loukia
Mavridis, Dimitris
Samara, Myrto
Barbui, Corrado
Engel, Rolf R
Geddes, John R
Salanti, Georgia
Davis, John M
Venue: The Lancet
Publisher: Elsevier BV
Published: 2013-09
Volume: 382
Issue: 9896
Pages: 951-962
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(13)60733-3
OpenAlex: W2009832071
Cited by: 2,561
References: 61
Citations by year: 2026: 134 · 2025: 135 · 2024: 161 · 2023: 146 · 2022: 182 · 2021: 215 · 2020: 223 · 2019: 221 · 2018: 217 · 2017: 228 · 2016: 255 · 2015: 243 · 2014: 160 · 2013: 36
FWCI: 164.63
Type: journal article
Language: en
Open access: closed
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Funders: National Institute for Health and Care Research (NF-SI-0611-10150)
H. Lundbeck A/S
Medical Research Council
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: schizophrenia, antipsychotic drugs, drug efficacy comparison, tolerability, Bayesian framework, weight gain, extrapyramidal symptoms, QTc prolongation, sedation, clozapine, amisulpride, olanzapine, risperidone, paliperidone, zotepine
MeSH terms: Adult, Humans, Schizophrenia, Antipsychotic Agents, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks